Celgene begins operations in Mexico
Celgene inicia operaciones en México
Intel ID : 227152
| Synopsis |
|
US-based pharmaceutical company Celgene began operations in Mexico, as reported by newspaper El Economista on 14 July 2015. Celgene's objective is to discover, develop and commercialize therapies for cancer and immune-inflammatory diseases. Currently, Celgene carries out approximately 300 clinical studies and has in excess of 50 pathologies under analysis, 25 treatments in clinical trials, and 15 drugs in research phase III, which prior to approval.
(content in spanish)
La biofarmacéutica estadounidense Celgene ha iniciado operaciones en México, según ha informado el diario El Economista el 14 de julio de 2015. La firma biofarmacéutica ha anunciado el inicio de sus operaciones en México con el objetivo de descubrir, desarrollar y comercializar terapias en áreas de onco-hematología y enfermedades inmuno-inflamatorias. En la actualidad, la biofarmacéutica realiza cerca de 300 estudios clínicos y cuenta con más de 50 patologías en estudio, 25 tratamientos en ensayos clínicos y 15 medicamentos en fase III de investigación, la fase previa a la aprobación. |
| Intel ID | 227152 | |
| Value | ND | |
| Native Currency |
US Dollar (USD)
Exchange Rate:  |
|
| Date |
|
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
 |
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.